Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.56 |
| ▸ | CES1 | P23141 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8938130 | 0.98 | CES2 (0.54) | CES2CES1ALDH1A1MAPK1TDP1 | |
| SCHEMBL2321260 | 0.85 | CES2 (0.41) | CES2CES1ALDH1A1MAPK1TDP1 | |
| SCHEMBL11407542 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPK1TDP1HDAC6 | |
| Water SCHEMBL11414574 | 0.78 | TDP1 (0.55) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL5471366 | 0.78 | CES2 (0.54) | CES2CES1ALDH1A1MAPK1TDP1 | |
| SCHEMBL3056544 | 0.78 | CES2 (0.63) | CES2CES1ALDH1A1MAPK1TDP1 | |
| Water SCHEMBL8938135 | 0.76 | CES2 (0.61) | CES2CES1ALDH1A1MAPK1TDP1 | |
| SCHEMBL360314 | 0.75 | MAPK1 (0.58) | CES2CES1ALDH1A1MAPK1TDP1 | |
| SCHEMBL18493798 | 0.75 | CES2 (0.50) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL18493797 | 0.75 | CES2 (0.50) | CES2CES1HCAR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2531492-B1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-9249130-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8809525-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2007039821-A2 | NOVEL INHIBITORS OF TYROSINASE, THEIR METHOD OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-12 | — | — | WO | disclosed |
| EP-0536896-B1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ALDH1A1 784/4885 |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ALDH1A1 784/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ALDH1A1 784/4885 |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 1924/4885CES1 632/4885ALDH1A1 794/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 2166/4885CES1 793/4885ALDH1A1 788/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | CES2 1939/4885CES1 675/4885ALDH1A1 763/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | CES2 1506/4885CES1 1376/4885ALDH1A1 251/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | CES2 2194/4885CES1 484/4885ALDH1A1 1211/4885 |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ALDH1A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.